The burden of undertreatment and non-treatment among patients with non-valvular atrial fibrillation and elevated stroke risk: a systematic review

CONCLUSIONS: Rates of nontreatment and undertreatment among NVAF patients remain high and are associated with preventable cardiovascular events and death. Strategies to increase rates of treatment may improve clinical outcomes.PMID:34632887 | DOI:10.1080/03007995.2021.1982684
Source: Current Medical Research and Opinion - Category: Research Authors: Source Type: research

Related Links:

We report our single-center experience with percutaneous left atrial appendage closure (LAAC) in patients with non-valvular atrial fibrillation (NVAF) and primary hemostasis disorders (HD).MethodsConsecutive patients with primary HD who underwent a percutaneous LAAC were included. Baseline characteristics, procedural data, and clinical outcomes were prospectively collected and compared with the overall LAAC cohort without HD.ResultsSince 2013, among 229 LAAC, 17 patients (7%) had a primary HD: thrombocytopenia (n = 5), myelodysplastic syndrome (n = 6), von Willebrand syndrome (n = ...
Source: Journal of Interventional Cardiac Electrophysiology - Category: Cardiology Source Type: research
Background: Hemorrhagic transformation (HT) after reperfusion therapy for acute ischemic stroke (AIS) has been well studied; however, there is scarce research focusing on spontaneous HT (sHT). Spontaneous HT is no less important with a relatively high incidence and could be associated with neurological worsening. We aimed to develop and validate a simple and practical model to predict sHT after AIS (SHAIS) and compared the predictive value of the SHAIS score against the models of post-Reperfusion HT for sHT.Methods: Patients with AIS admitted within 24 h of onset were prospectively screened to develop and validate the SHAI...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline dur...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Any screening program in the community, while providing useful and previously unknown information, has the potential of uncovering findings of uncertain interpretation, especially regarding their impact on clinical outcomes, and therefore the justification of extending the screening to larger cohorts with substantial health care costs. As Shang and colleagues [1] remind us, the STROKESTOP study [2] detected a modest benefit from screening for atrial fibrillation (AF) on the primary combined endpoint of ischaemic or haemorrhagic stroke, systemic embolism, bleeding leading to hospitalisation and all-cause death (1.1% absolut...
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Letter to the Editor Source Type: research
CONCLUSIONS: Approximately 30% of patients with AF and BPV replacement were treated with DOAC. The risks of major bleeding and stroke or systemic embolism were similar between warfarin- and DOAC-treated patients with AF who had BPV replacement. Treatment with DOACs could be an alternative to warfarin in this population.PMID:34719560 | DOI:10.1253/circj.CJ-21-0564
Source: Circulation Journal - Category: Cardiology Authors: Source Type: research
Nervenarzt. 2021 Oct 15. doi: 10.1007/s00115-021-01206-w. Online ahead of print.ABSTRACTOral anticoagulation in patients with cerebral amyloid angiopathy is a therapeutic challenge. The association of cerebral amyloid angiopathy with intracerebral hemorrhage, a high mortality of intracerebral hemorrhage especially under oral anticoagulation and the high risk of recurrent bleeding require a multidisciplinary approach and a thorough risk-benefit analysis. Vitamin K antagonists increase the risk of intracerebral bleeding and the accompanying mortality by 60% and should be avoided if possible or reserved for special clinical s...
Source: Der Nervenarzt - Category: Neurology Authors: Source Type: research
Herz. 2021 Aug 31. doi: 10.1007/s00059-021-05065-8. Online ahead of print.ABSTRACTCatheter-based left atrial appendage closure (LAAC) is currently a potential treatment option for stroke prevention in patients with atrial fibrillation and high risk for stroke/embolism as well as high bleeding risk. Due to improvements in LAAC devices, advances in implantation techniques and growing experience of the interventional teams, the safety profile of LAAC has significantly improved in recent years. These developments have led to a currently comprehensive exploration of novel indications for LAAC, such as patients with atrial fibri...
Source: Herz - Category: Cardiology Authors: Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Conferences | Coumadin | Databases & Libraries | Gastroenterology | Heart | Hemorrhagic Stroke | Research | Stroke | Study | Warfarin